| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.2215/CJN.03840907 |
| P698 | PubMed publication ID | 18077782 |
| P2093 | author name string | Iain C Macdougall | |
| P433 | issue | 1 | |
| P304 | page(s) | 200-207 | |
| P577 | publication date | 2007-12-12 | |
| P1433 | published in | Clinical Journal of the American Society of Nephrology | Q15757929 |
| P1476 | title | Novel erythropoiesis-stimulating agents: a new era in anemia management | |
| P478 | volume | 3 |
| Q35574041 | A meta-analysis of the relative doses of erythropoiesis-stimulating agents in patients undergoing dialysis |
| Q87422909 | A population-based study comparing biosimilar versus originator erythropoiesis-stimulating agent consumption in 6,117 patients with renal anaemia |
| Q30586178 | An update on the impact of pre-transplant transfusions and allosensitization on time to renal transplant and on allograft survival |
| Q46141374 | Anaemia and resistance to erythropoiesis-stimulating agents as prognostic factors in haemodialysis patients: results from the RISCAVID study |
| Q59507372 | Anemia Control in Kidney Transplant Patients Treated With Methoxy Polyethylene Glycol-Epoetin Beta (Mircera): The Anemiatrans Group |
| Q37923100 | Anemia of renal disease: what it is, what to do and what's new. |
| Q34485713 | BiOsimilaRs in the management of anaemia secondary to chemotherapy in HaEmatology and Oncology: results of the ORHEO observational study |
| Q41784569 | Biosimilar Retacrit® (epoetin zeta) in the treatment of chemotherapy-induced symptomatic anemia in hematology and oncology in Germany (ORHEO) - non-interventional study |
| Q37391931 | Biosimilar epoetin for the management of chemotherapy-induced anemia in elderly patients |
| Q55312853 | Cell-free protein synthesis as a novel tool for directed glycoengineering of active erythropoietin. |
| Q37307808 | Controversies in chronic kidney disease, anaemia and cardiovascular disease |
| Q39591373 | Detection of EPO-Fc fusion protein in human blood: screening and confirmation protocols for sports drug testing |
| Q40785295 | EPOR-Based Purification and Analysis of Erythropoietin Mimetic Peptides from Human Urine by Cys-Specific Cleavage and LC/MS/MS. |
| Q38161950 | Effectiveness and safety of erythropoiesis-stimulating agent use in the perioperative period |
| Q37696958 | Emerging erythropoiesis-stimulating agents |
| Q37646523 | Emerging technologies in the delivery of erythropoietin for therapeutics |
| Q37164738 | Epoetin-associated pure red cell aplasia: past, present, and future considerations |
| Q24201673 | Erythropoiesis stimulating agents for anaemia in adults with chronic kidney disease: a network meta-analysis |
| Q24187413 | Erythropoiesis-stimulating agents for anaemia in adults with chronic kidney disease: a network meta-analysis |
| Q37810966 | Erythropoiesis-stimulating agents for anemic patients with cancer |
| Q37098040 | Erythropoietic agents and the elderly |
| Q37403306 | Erythropoietin stimulating agents in the management of anemia of chronic kidney disease |
| Q50041581 | Genotoxic assessment and toxicity evaluation of peginesatide in CByB6F1 hybrid mice. |
| Q34612274 | Iron supplementation and mortality in incident dialysis patients: an observational study. |
| Q47371735 | JAK2/STAT5 signaling pathway mediates Bojungbangdocktang enhanced hematopoiesis |
| Q37157237 | Managing dialysis patients who develop anemia caused by chronic kidney disease: focus on peginesatide |
| Q38257399 | Methoxy polyethylene glycol-epoetin beta versus darbepoetin alfa for anemia in non-dialysis-dependent CKD: a systematic review. |
| Q37510916 | Methoxy polyethylene glycol-epoetin beta: worth waiting for or a novelty worn off? |
| Q43232912 | Molecular basis of cytokine signalling--theme and variations |
| Q34642348 | Once-monthly continuous erythropoietin receptor activator (CERA) for haemoglobin maintenance in haemodialysis patients with chronic renal anaemia |
| Q26764890 | Oxidative Stress during Ovarian Torsion in Pediatric and Adolescent Patients: Changing The Perspective of The Disease |
| Q22241420 | PEGylation of Interferon-β-1a |
| Q37893439 | Pattern of resistance to erythropoietin-stimulating agents in chronic kidney disease |
| Q37700912 | Peginesatide and erythropoietin stimulate similar erythropoietin receptor-mediated signal transduction and gene induction events |
| Q35944877 | Performance of a Predictive Model for Long-Term Hemoglobin Response to Darbepoetin and Iron Administration in a Large Cohort of Hemodialysis Patients |
| Q33531889 | Pharmacotherapy of end-stage renal disease |
| Q28822022 | Potent and selective chemical probe of hypoxic signalling downstream of HIF-α hydroxylation via VHL inhibition |
| Q39695661 | Purification and Characterization of Recombinant Darbepoetin Alfa from Leishmania tarentolae. |
| Q64244987 | RNA-seq analysis of PHD and VHL inhibitors reveals differences and similarities to the hypoxia response |
| Q38703514 | Recent advances in oral delivery of peptide hormones. |
| Q36655932 | Regulation of Erythropoietin Receptor Activity in Endothelial Cells by Different Erythropoietin (EPO) Derivatives: An in Vitro Study |
| Q38123955 | Renal anemia: from incurable to curable |
| Q37705178 | The Use of Darbepoetin to Stimulate Erythropoiesis in the Treatment of Anemia of Chronic Kidney Disease in Dogs. |
| Q40297731 | The use of darbepoetin to stimulate erythropoiesis in anemia of chronic kidney disease in cats: 25 cases |
| Q37368733 | Use of agents stimulating erythropoiesis in digestive diseases |
| Q42683540 | Visualization of 57Fe-Labeled Heme Isotopic Fine Structure and Localization of Regions of Erythroblast Maturation in Mouse Spleen by MALDI FTICR-MS Imaging |
| Q83387143 | [Biological similarity of erythropoietin: controlled maturation] |
| Q84569481 | [Erythropoietin: from the receptor to erythropoiesis stimulating agents] |
| Q54789339 | [Erythropoietin: receptor of stimulating agents of erythropoiesis]. |
| Q84569485 | [Hemoglobin stability: results of clinical trials] |
Search more.